Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses using MRD to guide therapy in acute myeloid leukemia (AML).
Sunvozertinib Shows Activity, Tolerable Safety in EGFR Exon20 Insertion-Positive NSCLC
June 6th 2023Phase 2 results have placed a novel EGFR exon 20 insertion inhibitors in the realm of possibilities for future treatment of previously-treated non–small cell lung cancer with EGFR exon 20 insertions in the tumor tissue.
Read More
Datopotamab Deruxtecan/Pembrolizumab Combo Show Anti-tumor Activity in Advanced NSCLC
June 6th 2023New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.
Read More
Eftilagimod Alpha Added to Pembrolizumab Induces Hopeful Responses in Metastatic HNSCC
June 6th 2023Eftilagimod alpha plus pembrolizumab showed an overall response rate of over 25% in patients with metastatic head and neck squamous cell carcinoma treated in the phase 2 TACTI-002 study.
Read More
Niraparib Maintenance Therapy Induces Antitumor Activity in Advanced Ovarian Cancer
June 6th 2023The use of maintenance niraparib therapy led to clinically meaningful improvement in progression-free survival, compared with placebo, in patients with newly diagnosed, advanced ovarian cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512